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Abstract
Background: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments.
Objective: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE.
Methods: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on
a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial
Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically
meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29
PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined
by baseline demographic/disease characteristics.
Results: Daclizumab beta significantly reduced risk of 24-week CDP (hazard ratio (HR), 0.73; 95% confidence interval (95% CI), 0.55–0.98), risk of 24-week sustained MSFCS progression (HR, 0.80; 95% CI,
0.67–0.95), and odds of clinically meaningful worsening in MSIS-29 PHYS (odds ratio, 0.76; 95% CI,
0.60–0.95) versus IM interferon beta-1a. Point estimates showed trends favoring daclizumab beta over IM
interferon beta-1a across several patient subgroups for all three outcome measures.
Conclusion: Daclizumab beta showed consistent benefit versus IM interferon beta-1a across measures
assessing patient disability/function and across a range of clinical baseline characteristics in patients with
relapsing-remitting MS.

Keywords: Daclizumab beta, disability progression, efficacy, interferon beta-1a, relapsing-remitting
multiple sclerosis, subgroup analysis
Date received: 19 June 2017; revised: 8 September 2017; accepted: 10 September 2017

Introduction
Delaying progression of disability is a key therapeutic
goal of disease-modifying therapy (DMT) in patients
with multiple sclerosis (MS).1,2 Multiple outcome
measures have been developed to assess disease progression or patient function in clinical studies of
patients with MS. The Expanded Disability Status
Scale (EDSS) is the most established outcome measure in MS clinical trials.3,4 The EDSS has notable

journals.sagepub.com/home/msj

limitations, particularly with regard to insensitivity in
upper extremity function and non-motor functions
once ambulation is severely restricted.2,5–7 Additionally,
it does not provide an adequate assessment of cognitive impairment related to MS.6
The Multiple Sclerosis Functional Composite
(MSFC), developed to overcome some of the limitations of the EDSS, comprises three components that
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evaluate different patient functional outcomes: the
Timed 25-Foot Walk (T25FW) for ambulation, the
9-Hole Peg Test (9HPT) for hand/arm dexterity, and
the 3-Second Paced Auditory Serial Addition Test
(PASAT-3) for cognition.7 Because clinical interpretation of the composite z-score methodology employed
for the MSFC can be challenging, examining worsening of each MSFC component separately has been
proposed as an alternative analytic measure.8 It has
also been suggested that the MSFC is a more robust
assessment if the Symbol Digit Modalities Test
(SDMT) is used instead of the PASAT-3 for assessing
cognition.6,9 The SDMT is easier and faster to administer,10 may be more reliable,6,9,11 and has demonstrated smaller practice effects,9 a known concern
with the PASAT-3.12
DECIDE (NCT01064401) was a phase 3 study that
evaluated the efficacy and safety of treatment with
daclizumab beta 150 mg subcutaneous once every
4 weeks versus interferon (IFN) beta-1a 30 mcg intramuscular (IM) once weekly in patients with relapsing-remitting MS (RRMS).13 Daclizumab beta
(formerly known as daclizumab high-yield process)
was approved as ZINBRYTA®, which has a different
form and structure than an earlier form of daclizumab.
In the overall study population, daclizumab beta demonstrated greater benefit compared with IM IFN beta1a on several outcome measures of disability. While
12-week confirmed disability progression (CDP) as
assessed by EDSS did not differ significantly between
the two treatment groups, 24-week CDP, a more
robust outcome than 12-week CDP, was reduced by
27% in patients treated with daclizumab beta versus
IM IFN beta-1a (p = 0.033).13 At week 96, patients in
the daclizumab beta versus the IM IFN beta-1a group
had greater median change from baseline (25th, 75th
percentiles) in overall MSFC score (0.091 (−0.096 to
0.287) vs 0.055 (−0.136 to 0.240), respectively;
p < 0.001), in each individual MSFC component score
(all p < 0.05), and a greater mean change on the SDMT
(p = 0.03).13 Additionally, patients in the daclizumab
beta group had a 24% reduction in the odds of experiencing a clinically meaningful worsening in the
patient-reported 29-Item Multiple Sclerosis Impact
Scale physical impact subscale (MSIS-29 PHYS)
score at week 96 (odds ratio (OR), 0.76; 95% confidence interval (95% CI), 0.60–0.95; nominal
p = 0.0176).14
In addition to demonstrating efficacy of an MS therapy in the overall study population, subgroup analyses may inform on treatment effects across different
demographic and clinical characteristics.15,16 This
post hoc analysis examined treatment effects of
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daclizumab beta compared with IM IFN beta-1a on
measures of patient disability or impairment across
patient subgroups according to baseline demographic
and disease characteristics in DECIDE. The measures
included a modified MSFC, in which the PASAT-3
was replaced with the SDMT.
Methods
Full details of DECIDE have been reported.13 Briefly,
patients of age 18–55 years with a confirmed diagnosis
of RRMS were randomized (1:1) to daclizumab beta
150 mg subcutaneous every 4 weeks and IM placebo
once weekly or IFN beta-1a 30 mcg IM once weekly
and subcutaneous placebo every 4 weeks for a minimum of 96 weeks and up to 144 weeks. Magnetic resonance imaging (MRI) consistent with MS, baseline
EDSS score of 0–5.0, and two or more relapses within
the previous 3 years (one or more in year before study)
or one or more relapse(s) and one or more new MRI
lesion(s) within 2 years (one or more event(s) in year
before study) constituted additional inclusion criteria.
All patients provided written informed consent.
Central and local ethics committee approvals were
obtained, and the study was performed in accordance
with the Declaration of Helsinki and the International
Conference on Harmonisation Guidelines for Good
Clinical Practice.17
Assessments
Three outcome measures of patient disability/function
were examined for the overall study population and by
subgroup. These included 24-week CDP as measured
by EDSS18 (tertiary endpoint in DECIDE), 24-week
sustained worsening on the MSFCS (analysis performed post hoc), and the proportion of patients experiencing a clinically meaningful worsening in MSIS-29
PHYS score at week 96 (secondary endpoint in
DECIDE). Twenty-four-week CDP was defined as an
increase in the EDSS score of ⩾1.0 point(s) from a
baseline score of ⩾1.0 or ⩾1.5 points from a baseline
score of 0 confirmed after 24 weeks.13 Twenty-fourweek sustained worsening on the MSFCS, based in
part on an analysis by Rudick et al.,8 was defined as
⩾20% worsening in T25FW score, ⩾20% worsening
in 9HPT score (mean of both hands), or a decrease of
⩾4 points in SDMT score (clinically meaningful
change)19 sustained for 24 weeks. Additional analyses
were run using alternative methods for evaluating
9HPT. These included examining a 20% worsening in
9HPT score for the dominant hand only or for either
the dominant hand or the non-dominant hand. Finally,
in order to capture clinically meaningful changes due
to MS from the patents’ perspective, worsening from
journals.sagepub.com/home/msj
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baseline in MSIS-29 PHYS score was analyzed at
week 96. An increase from baseline on the MSIS-29 of
⩾7.5 points has been shown to indicate clinically
meaningful worsening in a large clinical study
population.20
EDSS, T25FW, and 9HPT scores were assessed at
baseline and every 12 weeks until week 144 (or end of
study). SDMT (oral response format) and MSIS-29
(version 1) scores were assessed at baseline and every
24 weeks until week 144 or end of study.
Subgroups based on baseline demographics were age
(⩽35, >35 years) and sex (female, male). Subgroups
based on baseline disease characteristics were disability as defined by EDSS score (<3.5, ⩾3.5), relapses in
previous 12 months (one or less, two or more), disease
duration (<3, ⩾3 to <10, or ⩾10 years), gadoliniumenhancing (Gd+) lesions (absent, present), T2 hyperintense lesion volume (<, ⩾ median), disease activity
(highly active, less active; highly active was defined
as two or more relapses in the year before randomization and one or more Gd+ lesion(s) on baseline MRI,
less active otherwise), prior DMT use (yes, no;
excluding steroids but including any prior diseasemodifying or immunomodulatory therapy for MS,
such as alemtuzumab, azathioprine, cladribine, cyclophosphamide, fingolimod, fumaric acid, glatiramer
acetate, immune globulin, IFN beta-1a, IFN beta-1b,
laquinimod, methotrexate, mitoxantrone, mycophenolic acid, natalizumab, teriflunomide, or temsirolimus), and prior IFN beta use (yes, no; including IFN
beta, IFN beta-1a, and IFN beta-1b).
Statistical analyses
All analyses were performed on the intention-to-treat
population (randomized patients who received one or
more dose(s) of study drug) with non-missing baseline
assessments.13 p-values reported were not adjusted for
multiple testing. Disability progression based on
EDSS score was analyzed by a Cox proportional hazards model adjusted for baseline EDSS score (continuous variable), prior IFN beta use (yes, no), and baseline
age (⩽35, >35 years), excluding covariates defining
the subgroup. Among patients with one or more tentative progression event(s), a logistic model was used to
estimate the probability of confirmation for patients
with a missing EDSS assessment to confirm progression. The logistic model adjusted for treatment group,
EDSS score at baseline (continuous variable), change
in EDSS score from baseline to the time of tentative
progression, and presence or absence of a relapse
within the last 29 days of the tentative progression.13
For patients with multiple tentative progressions, the
journals.sagepub.com/home/msj

confirmed (if patient had a confirmed progression) or
the last (if patient did not have any tentative progressions confirmed) tentative progression record was
retained. In total, 50 imputed datasets were generated
using the estimated probabilities from this logistic
regression model. The Cox proportional hazards
model was conducted on subgroups of each of the 50
datasets. Rubin’s rule21 was used to combine the HR,
standard error of this estimate, and p-values.
MSFCS progression was analyzed by Cox proportional hazards model adjusted for prior IFN beta use
(yes, no) and baseline age (⩽35, >35 years), excluding covariates defining the subgroup. Patients with a
tentative progression at the end of treatment period
visit and no confirmation assessment were censored
at their last assessment. Data were re-censored at
2 years, that is, 96 weeks. Missing T25FW and 9HPT
data were imputed using the method described in the
supplemental material of Kappos et al.13 Missing
SDMT values in post-baseline visits were imputed
using last observation carried forward. For patients
with missing SDMT values, the other endpoints were
used to derive time to first sustained progression.
Analyses of patients with a clinically meaningful worsening in MSIS-29 PHYS score were based on logistic
regression models, adjusted for baseline MSIS-29 PHYS
score, baseline Beck Depression Inventory-II score,
prior IFN beta use, and baseline age (⩽35, >35 years),
but excluded covariates defining the subgroup. If a
patient was missing data for <10 of the 20 items that
make up the PHYS score, then the mean of the nonmissing items was used for the missing items. If the
patient was missing ⩾10 of the 20 items that make up
the PHYS score, or missing the questionnaire entirely, or
if the questionnaire was completed after the patient
switched to alternative MS medication, a random effects
model was used to estimate MSIS-29 PHYS score.
Results
The intention-to-treat population of DECIDE included
1841 patients; 922 were randomized to IM IFN beta1a and 919 were randomized to daclizumab beta.13
Details of the demographics and baseline characteristics of the DECIDE study population are published.13
Relevant demographics and baseline characteristics
are shown in Table 1.
Twenty-four-week CDP
Across all subgroups, point estimates of the risk of
24-week CDP showed consistent trends favoring
daclizumab beta over IM IFN beta-1a (Figure 1) and
1885
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Table 1. Patient demographics and baseline disease characteristics in DECIDE.
Characteristic
Age, years, mean (SD)
Female, n (%)
White, n (%)
Time since MS diagnosis, years, mean (median)
Number of relapses in previous year, mean (SD)
Number of relapses in previous 3 years,a mean (SD)
Baseline EDSS score
Mean (SD)
Median (range)
SDMT score,b mean (SD)
MSIS-29 PHYS score,c mean (SD)
MSIS-29 PSYCH score,d mean (SD)
MSFC score,e median (25th, 75th percentiles)
T25FW z-score
9HPT z-score
PASAT-3 z-scorec

IM IFN beta-1a (n = 922)
36.2 (9.3)
627 (68)
828 (90)
4.1 (2.0)
1.6 (0.8)
2.7 (1.3)
2.5 (1.3)
2.3 (0−6.0)
47.7 (16.1)
21.9 (19.2)
28.6 (21.1)
0.118 (−0.377, 0.482)
0.223 (−0.042, 0.372)
0.035 (−0.622, 0.633)
0.264 (−0.619, 0.794)

Daclizumab beta (n = 919)
36.4 (9.4)
625 (68)
823 (90)
4.2 (2.0)
1.5 (0.7)
2.7 (1.2)
2.5 (1.2)
2.0 (0−5.5)
48.5 (15.9)
21.5 (19.8)
28.8 (21.8)
0.139 (−0.335, 0.491)
0.223 (−0.034, 0.372)
0.065 (−0.597, 0.661)
0.352 (−0.531, 0.794)

IM: intramuscular; IFN: interferon; SD: standard deviation; MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; SDMT:
Symbol Digit Modalities Test; MSIS-29: 29-Item Multiple Sclerosis Impact Scale; PHYS: physical impact subscale; PSYCH:
psychological impact subscale; MSFC: multiple sclerosis functional composite; T25FW: Timed 25-Foot Walk; 9HPT: 9-Hole Peg
Test; PASAT-3: 3-Second Paced Auditory Serial Addition Test.
aDaclizumab beta, n = 918.
bIM IFN beta-1a, n = 880; daclizumab beta, n = 884.
cIM IFN beta-1a, n = 912; daclizumab beta, n = 906.
dIM IFN beta-1a, n = 912; daclizumab beta, n = 904.
eIM IFN beta-1a, n = 920; daclizumab beta, n = 916.

supported the results observed for 24-week CDP in
the overall study population.13 For this outcome
measure, minor variations in treatment effect estimates were observed and there was no convincing
evidence of effect modification. HRs ranged from
0.46 to 0.87, where the greatest risk reduction was
observed in patients ⩽35 years of age.

Twenty-four-week sustained MSFCS progression
Fewer daclizumab beta (24% (224/919)) versus IM IFN
beta-1a patients (28% (259/922)) met the criteria for
24-week sustained MSFCS progression at week 96. Of
patients who progressed, MSFCS progression was most
commonly driven by SDMT (IM IFN beta-1a, 56%
(146/259); daclizumab beta, 55% (124/224)), followed
by T25FW (IM IFN beta-1a, 34% (89/259); daclizumab
beta, 33% (75/224)) and 9HPT scores (IM IFN beta-1a,
6% (16/259); daclizumab beta, 8% (17/224)). The rest of
the patients progressed on two or more components at
the same time. In the overall study population, treatment
with daclizumab beta resulted in a 20% reduction (HR,
0.80; 95% CI, 0.67–0.95; p = 0.0132) in risk of 24-week
sustained MSFCS progression compared with IM IFN
beta-1a. Point estimates of risk of 24-week sustained
1886

progression of the MSFCS show consistent trends favoring daclizumab beta over IM IFN beta-1a across all subgroups. HRs ranged from 0.56 to 0.92. While there were
minor variations in treatment effect estimates, there was
no convincing evidence of effect modification (Figure
2). Nominal statistical significance of risk reduction was
noted for age ⩽ 35 years, baseline EDSS score ⩾3.5, two
or more relapses in the previous year, presence of baseline Gd+ lesions, T2 hyperintense lesion volume
⩾median, less active disease activity at baseline, no
prior DMT use, no prior IFN beta use, and time since
diagnosis ⩾10 years. Similar results were observed
when alternative methods were used for assessing 9HPT
score (both dominant and non-dominant hands included,
dominant hand only; Figure S1).

Clinically meaningful worsening in MSIS-29
PHYS score
Treatment with daclizumab beta resulted in a 24%
reduction in the odds of a clinically meaningful worsening in MSIS-29 PHYS score at week 96 versus IM
IFN beta-1a (OR, 0.76; 95% CI, 0.60–0.95;
p = 0.0176).13 ORs of the risk of clinically meaningful worsening in MSIS-29 PHYS score at week 96
journals.sagepub.com/home/msj
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Figure 1. Forest plot for 24-week confirmed disability progression for daclizumab beta versus IM IFN beta-1a by
baseline demographics and disease characteristics.
CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN: interferon; IM: intramuscular; MS:
multiple sclerosis; SC: subcutaneous.
aMissing baseline Gd+ lesions data: IM IFN beta-1a, n = 13; daclizumab beta, n = 19.
bMissing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 14; daclizumab beta, n = 19.
cMissing baseline disease activity data: IM IFN beta-1a, n = 5; daclizumab beta, n = 12.

show trends favoring daclizumab beta over IM IFN
beta-1a across all subgroups (Figure 3). ORs ranged
from 0.57 to 0.97. Nominal statistical significance of
risk reduction was noted for female sex,
age ⩽ 35 years, disease duration <3 years, baseline
EDSS score <3.5, two or more relapses in previous
year, presence of baseline Gd+ lesions, T2 hyperintense lesion volume ⩾median, no prior DMT use,
and no prior IFN beta use.

IFN beta-1a across multiple patient subgroups, thus
supporting the treatment effect seen in the overall population for each of the outcome measures examined
independent of baseline characteristics. Treatment
effect did not reach statistical significance for all subgroups for any of the three outcome measures, however, age ⩽ 35 years and baseline T2 hyperintense
lesion volume ⩾median reached nominal significance
for all three measures.

Discussion
In the overall study population of DECIDE, treatment
with daclizumab beta resulted in significant reductions
in risk of 24-week CDP as measured using the EDSS,
and risk of 24-week sustained progression on the
MSFCS, a version of the MSFC replacing the PASAT-3
with the SDMT. Additionally, patients receiving daclizumab beta had reduced risk of experiencing a clinically meaningful worsening in MSIS-29 PHYS score
compared with IM IFN beta-1a. Daclizumab beta
treatment also showed consistent benefit versus IM

In this study, daclizumab beta demonstrated greater
efficacy versus IM IFN beta-1a on two distinct measures of disability progression, 24-week CDP as measured by EDSS and the MSFCS. Despite its wide use,
the EDSS has been criticized for a lack of sensitivity
to change and inadequate assessment of cognition.5,22
The MSFC was developed to address these limitations and provide information supplemental to that
provided by the EDSS.7 Both a 15% and a 20% worsening from baseline in at least one MSFC component
(sustained for 3 months) were found to be sensitive
measures of disability progression.8

journals.sagepub.com/home/msj
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Figure 2. Forest plot for 24-week sustained modified Multiple Sclerosis Functional Composite progression for
daclizumab beta versus IM IFN beta-1a by baseline demographics and disease characteristics.
CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; IFN: interferon; IM: intramuscular; MS:
multiple sclerosis; SC: subcutaneous.
aMissing baseline Gd+ lesions data: IM IFN beta-1a, n = 13; daclizumab beta, n = 19.
bMissing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 14; daclizumab beta, n = 19.
cMissing baseline disease activity data: IM IFN beta-1a, n = 5; daclizumab beta, n = 12.

This study examined MSFCS progression sustained
for 6 months, which is considered more robust than
the 3-month interval and is recommended by the
European Medicines Agency when examining
CDP.2,23 This study also explored three methodologies
for the 9HPT component of the MSFCS: mean of both
hands, dominant hand only, and either the dominant
or non-dominant hand. The results of this MSFCS
analysis did not appear to be impacted by choice of
methodology.
Rudick et al. reported that, of patients who progressed on the MSFCS using a 20% worsening, the
majority of patients progressed first on the T25FW
(51% of placebo and 54% of natalizumab), while
few patients progressed first on the PASAT-3 (5% of
placebo and 6% of natalizumab).8 In contrast, the
present analysis found that the majority of the
patients with MSFCS progression worsened first on
the SDMT, suggesting that the SDMT has potentially greater sensitivity compared with the PASAT-3
in detecting cognitive decline.
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In contrast to the EDSS and MSFC, which are clinical
assessment measures administered by physicians or
trained professionals, the patient-reported MSIS-29
was developed as a disease-specific tool meant to
capture the impact of MS from the perspective of the
patient.24 Point estimates from the subgroup analyses
of the proportion of patients with clinically meaningful worsening in the MSIS-29 PHYS consistently
favored daclizumab beta versus IM IFN beta-1a.
These analyses should be interpreted as exploratory
and hypothesis generating for future studies. Some
subgroups had small sample sizes, which resulted in
wider CIs for these subgroups.15 Additionally, no
adjustments were made for multiple testing. Inherent
differences in the properties of the tools (e.g. clinicianadministered vs patient-reported) and the different
functions assessed by each also may contribute to the
differences observed across them.25
Overall, the results of these post hoc subgroup analyses
of outcome measures assessing disability progression,

journals.sagepub.com/home/msj
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Figure 3. Forest plot for proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis
Impact Scale physical impact subscale score at week 96 for daclizumab beta versus IM IFN beta-1a by baseline
demographics and disease characteristics.
aOnly

patients with available baseline assessment were included in the overall MSIS-29 PHYS analysis.
included in the overall MSIS-29 PHYS analysis with missing baseline Gd+ lesions data: IM IFN beta-1a, n = 12; daclizumab
beta, n = 17.
cPatients included in the overall MSIS-29 PHYS analysis with missing baseline T2 hyperintense lesion volume data: IM IFN beta-1a,
n = 13; daclizumab beta, n = 17.
dPatients included in the overall MSIS-29 PHYS analysis missing baseline disease activity data: IM IFN beta-1a, n = 4; daclizumab beta,
n = 11.
bPatients

as well as patient-reported function, indicate that the
efficacy of daclizumab beta treatment compared with
IM IFN beta-1a was superior and consistent across a
range of baseline demographic and disease characteristics in patients with RRMS in DECIDE.
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